Neuronetics_logo-RGB purple.png
Neuronetics and Greenbrook TMS Announce Six Year Exclusive Partnership
January 19, 2023 08:30 ET | Neuronetics
MALVERN, Pa. and TORONTO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing, and marketing products...
Neuronetics_logo-RGB purple.png
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 18, 2023 16:29 ET | Neuronetics
MALVERN, Pa., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics_logo-RGB purple.png
Neuronetics Announces Data Confirming Efficacy in Treating Anxious Depression with NeuroStar® Advanced Therapy for Mental Health
January 17, 2023 08:32 ET | Neuronetics
MALVERN, Pa., Jan. 17, 2023 (GLOBE NEWSWIRE) --  Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics_logo-RGB purple.png
Neuronetics Settles Litigation Against BrainsWay
January 10, 2023 08:00 ET | Neuronetics
MALVERN, Pa., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics_logo-RGB purple.png
Neuronetics Reports Preliminary Fourth Quarter and Fiscal Year 2022 Financial Results
January 09, 2023 08:30 ET | Neuronetics
MALVERN, Pa., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics_logo-RGB purple.png
Neuronetics Announces Appointment of Joseph H. Capper to its Board of Directors
December 29, 2022 16:29 ET | Neuronetics
MALVERN, Pa., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever...
Neuronetics_logo-RGB purple.png
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 07, 2022 16:30 ET | Neuronetics
MALVERN, Pa., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics_logo-RGB purple.png
Neuronetics Announced as a Winner by 2022 Merit Awards for HealthCare in the Patient Care Category
December 05, 2022 08:32 ET | Neuronetics
MALVERN, Pa., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics_logo-RGB purple.png
Neuronetics to Present at the Piper Sandler 34th Annual Healthcare Conference
November 21, 2022 16:30 ET | Neuronetics
MALVERN, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics_logo-RGB purple.png
Neuronetics Announces NeuroStar® Advanced Therapy for Mental Health System Innovations
November 14, 2022 08:33 ET | Neuronetics
MALVERN, Pa., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...